Ex Parte BILLMERS et al - Page 6




          Appeal No. 2002-2261                                                        
          Application No. 09/568,111                                                  


          discloses that a hydrophobically modified amylose-containing                
          starch base coated paper that is further extruded with polyolefin           
          impedes the permeability of oxygen" (sentence bridging pages 4              
          and 5 of Brief), appellants have not addressed the examiner's               
          citation of Lacz '450 which teaches a preference for high amylose           
          starch containing more than 50 weight percent amylose (see column           
          3, lines 25-28).  Also, as explained above, Lacz '450 attributes            
          oxygen impermeability to the coating of amylose starch, not the             
          extruded polyolefin.  As a result, we cannot subscribe to                   
          appellants' position that "the Examiner has failed to establish a           
          prima facie case of obviousness based on the combination of Lacz            
          '450 and Lacz '473" (page 5 of Brief, second paragraph, emphasis            
          added).                                                                     
               Appellants also rely upon the asserted unexpected superior             
          Gurley porosity demonstrated in the present specification,                  
          Table 1, samples 1 and 4.  However, appellants have not                     
          shouldered their initial burden of establishing that the                    
          specification results would be considered truly unexpected by one           
          of ordinary skill in the art, especially in light of the                    
          disclosure in Lacz '450 that the claimed high amylose starch and            
          polyvinyl alcohol provide increased oxygen impermeability.  In re           
          Merck & Co., 800 F.2d 1091, 1099, 231 USPQ 375, 381 (Fed. Cir.              

                                         -6-                                          





Page:  Previous  1  2  3  4  5  6  7  8  9  Next 

Last modified: November 3, 2007